Background. Fractional-dose administration of inactivated poliovirus vaccine (fIPV) could increase IPV affordability and stretch limited supplies. We assessed immune responses following fIPV administered intradermally, compared with full-dose IPV administered intramuscularly, among adults with a history of oral poliovirus vaccine (OPV) receipt.
The World Health Assembly resolved in 1998 to eradicate poliomyelitis worldwide by 2000. Substantial progress toward eradication was made since 1988, with a decline in the number of polio-endemic countries from 125 to 3 and a decrease in the incidence of wild poliovirus-associated cases from approximately 350 000 in 1988 to 32 in 2016, including 4 wild poliovirus type 1-associated cases with paralysis onset in Nigeria during July and August 2016 (as of 15 November 2016) [1, 2] . In addition, wild poliovirus types 2 and 3 have not been detected globally since October 1999 and November 2012, respectively [3, 4] . These achievements were accomplished primarily through the widespread use of oral poliovirus vaccine (OPV), with trivalent OPV used initially and bivalent OPV and monovalent OPV used more recently, during supplementary immunization activities [5] .
The eradication of poliovirus requires the global cessation of OPV use [6] , because of the rare but significant risk of vaccinederived polioviruses to reestablish transmission; in 2016, 3 circulating vaccine-derived poliovirus-associated cases were reported (as of 24 August 2016) [7, 8] . Furthermore, OPV can cause vaccine-associated paralytic poliomyelitis, with an estimated risk of 2-4 cases per million births per year [5] . To secure eradication, the Global Polio Eradication Initiative recommended the sequential elimination of Sabin strains from the trivalent OPV, starting with Sabin type 2 poliovirus in April 2016 [1] , ideally preceded by the introduction of at least 1 dose of IPV [9] .
A dose of IPV will induce an immunization base against poliovirus type 2 that is expected to mitigate the risk of paralytic disease (should poliovirus type 2 circulate after cessation of Sabin type 2 poliovirus use). A second dose of IPV (together with monovalent OPV type 2), as may be needed for an outbreak response, will likely rapidly close any remaining immunity gaps and boost antibody titers [10] . In addition, multiple doses of monovalent OPV against Sabin type 2 poliovirus would be expected to induce mucosal immunity that should decrease further transmission [11] . Although IPV is widely used in industrialized countries, developing countries have only recently gained access to this product. Since 2013, 103 of 126 countries using OPV only have introduced at least 1 dose of IPV into their routine immunization programs [12] . Despite the support of the Global Alliance for Vaccines and Immunization, the affordability of IPV remains an issue for developing countries [13] .
Furthermore, the massive scale-up in production of IPV required by the 2 main suppliers has repeatedly faced technical challenges, resulting in reductions of approximately 50% in the initial supply commitments during 2015-2016 [14] . These shortages have significantly limited the number of doses available to countries, resulting in >50 countries either facing delay in IPV introduction or stockouts after IPV introduction [15] .
In this context, the World Health Assembly recommended pursuing strategies to develop affordable and accessible IPV for developing countries [16] . Several approaches could make IPV more affordable and may result in dose sparing, including the use of fractional-dose IPV (fIPV) [17] . fIPV, which delivers one fifth of the IPV dose, has generated promising results [18] [19] [20] [21] [22] , and in April 2012 the Strategic Advisory Group of Experts on immunization recommended accelerating the development of fIPV [23] .
In close collaboration with Bilthoven Biologicals and the Dutch National Regulatory Authority, a noninferiority study was designed to assess the immune response following receipt of a booster dose of a fIPV, in previously OPV-vaccinated adults in Cuba.
METHODS

Study Design
We conducted a 2-arm, randomized, controlled noninferiority clinical trial in 14 health centers in Camaguey Province, Cuba, between 5 December 2014 and 17 September 2015, comparing 1 or 2 doses of fIPV (each containing one fifth of the full dose) with 1 or 2 doses of IPV (each containing the full dose). IPV was supplied in 3-mL glass vials sealed with a rubber septum. Each vial contained a single dose of 0.5 mL of vaccine, packaged in an outer box; each 0.5-mL dose contained 40, 8, and 32 DU of inactivated Salk poliovirus types 1, 2, and 3, respectively. A single dose was withdrawn from each vial. Opened vials were used within 15 minutes and then discarded. Participants received 0.1 mL intradermally or 0.5 mL intramuscularly of this vaccine.
Study Population
Healthy adult males aged 15-30 years were eligible if they had a history of receiving 6 doses of poliovirus vaccine during childhood as part of the Cuban National Immunization Program and gave voluntary informed consent. Exclusion criteria included poliovirus vaccination after 12 years of age, known or suspected exposure to wild poliovirus, receipt of any vaccination in the preceding 3 months, or known contraindications to vaccination. Participants were examined by a physician to determine eligibility, before enrollment.
We enrolled healthy adults with a history of childhood polio vaccination into our study because our primary aim was to assess the immune response in participants most likely to have low baseline poliovirus antibody titer. Participants fulfilling all inclusion criteria and none of the exclusion criteria were assigned in a 1:1 ratio to one of 2 study arms to receive either fIPV or IPV.
Study Oversight
The study was approved by the Cuban National Regulatory Agency; the Institutional Review Board of the Pedro Kouri Institute (Havana, Cuba); the ethical review committee of the Provincial Center for Hygiene, Epidemiology, and Microbiology (Camaguey, Cuba); and the ethics review committees of the Pedro Kouri Institute (Havana) and the World Health Organization (Geneva, Switzerland). The study was conducted in compliance with good clinical practice guidelines and Cuban national legal and regulatory requirements. All study vaccines were donated by Bilthoven Biologicals, which had no role in the study design and implementation, data analysis, manuscript preparation, or the decision to submit the manuscript for publication.
Randomization and Masking
The study randomization list containing participant numbers and their corresponding study arms was prepared by the study biostatistician independently of the study investigators and distributed to participating health centers. Participants fulfilling all inclusion criteria and no exclusion criteria were assigned in a 1:1 ratio to one of 2 study arms to receive either fIPV or IPV. Enrolled participants chose a sealed opaque envelope from available envelopes just prior to the administration of the vaccine; the envelope contained the assigned participant number, which corresponded to one of 2 study arms, as indicated on the randomization list. During the study period, there was no contact between the biostatistician and the study site investigators.
Study Procedures
Participants presented for 4 study visits to the health center (on days 0, 7, 28, and 56). At each visit, a 5-mL blood specimen was collected from each participant. The study vaccine (fIPV or IPV) was administered on days 0 and 28 after blood was collected. On days 28 and 56, blood was collected within a window period of 3 days before or after day 28 (days 25-31) or day 56 (days 53-59). Participants were observed for 60 minutes after each vaccination. A diary visit for a physician was done to check the adverse events, and a diary listing solicited adverse events was given to each participant to record any adverse events in the first 4 days following vaccination. The size of injection site reaction was measured by the physician, using a standardized measuring device that was provided to all participating health centers. Adverse events were identified by site investigators and reviewed by the principal investigator. Serious adverse events were reviewed by the data and safety monitoring board.
The primary end point was immune response defined as the proportion of participants with a change from nondetectable antibody (titer <1:8 dilution) to detectable antibody (seroconversion) after vaccine administration or a ≥4-fold increase in titer for participants with detectable antibodies ( for those with a baseline titer ≥1:8; boosting) on days 7 and 28 after administration of a single vaccine dose and on day 56 after administration of 2 vaccine doses. The secondary end point was safety, as assessed by the number and severity of local and systemic adverse reactions. Collected serum samples were tested at the Pedro Kourí Tropical Medicine Institute, the national polio laboratory in Havana and part of the Global Polio Laboratory Network. Samples were tested in triplicate, using a standardized microneutralization assay for antibodies to poliovirus types 1, 2, and 3 at doubling titrations of 1:8 up to 1:4096. The highest reported titer is 1:≥5664.
Statistical Analysis
Participants who met the study requirements, including attending all study visits and providing sufficient quantities of sera, were included in the final analysis (the modified intention-totreat population). The sample size calculation was determined in consultation with the Dutch National Regulatory Authority, with the following assumptions: a 10% noninferiority margin, an α level of 0.05 and a β level of 0.10 (ie, 90% power) for a 2-tailed test, and an expected boosting immune response of at least 85% after 1 dose of IPV or fIPV. These assumptions yielded a sample size of 269 participants per study arm; factoring a drop out rate of <10% (31 participants per study arm), the total sample size was 600 participants (300 per study arm).
We conducted the statistical analyses with R (version 2.9.2) [24] . The proportion of participants who seroconverted, the proportion with a 4-fold rise in antibody titer, and the median antibody titers were analyzed by visit, study arm, and poliovirus serotype. Differences in seroconversion rates and immune response between the study arms were tested using the Fisher exact test. For median antibody titers, P values were calculated using the Wilcoxon rank sum test, with 95% confidence intervals (CIs) calculated using bootstrapping with 10 000 replications [25] . The noninferiority of immune response rates was defined as the upper end of the 95% CI of the difference in the proportions of subjects in the IPV and fIPV study arms who had an immune response within a predefined noninferiority margin (10%) for all 3 poliovirus serotypes [26] . In addition, reverse cumulative distribution curves were composed to demonstrate antibody titer distribution by visit, study arm, and poliovirus serotype.
RESULTS
Enrollment took place between 5 December 2014 and 8 January 2015, with field procedures completed before the national immunization campaign with OPV, in March 2015, and laboratory and data analyses completed by September 2015. Among 676 adults assessed, 534 were enrolled in the study; 268 of 534 and 266 of 534 were randomly assigned to the fIPV and IPV study arms, respectively. Overall, of the 534 enrolled participants, 503 (94.2%) completed the study.
All 534 enrolled participants were male, with a mean age of 24 years for both study arms. Baseline demographic characteristics and type-specific seroprevalence levels are shown for each study arm in Table 1 . Baseline seroprevalence levels were higher for type 1 (91.0% in the fIPV arm, and 87.6% in the IPV arm) and type 2 (88.4% and 87.2%, respectively) than type 3 (70.2% and 66.9%, respectively). There were no significant differences between the 2 study arms in age and baseline seroprevalence levels for poliovirus serotypes 1, 2, and 3.
Our primary aim was to assess the immune response (ie, seroconversion or 4-fold increase in titer), because study participants had not been immunized in >10 years and were most likely to have already seroconverted and to have low baseline antibody titers. Seroconversion means the changes from seronegative to seropositive status, which, in the case of polio, is equivalent to protection against paralytic disease, whereas the immune response captures both seroconversion and the boosting response (ie, more than 4-fold increase in antibody titer) in individuals who are already seropositive. We present results for both seroconversion, as well as immune response. Immunogenicity results are displayed in Tables 2, 3 , and 4 (which present type-specific immunogenicity results, by study arm), Supplementary All participants were male. P values were calculated using the Student t test (for continuous variables) and the χ 2 test (for categorical variables). None of the differences between the arms were statistically significant (age, P = .54; serotype 1, P = .20; serotype 2, P = .67; and serotype 3, P = .42).
Abbreviations: CI, confidence interval; fIPV, fractional-dose inactivated polio vaccine; IPV, inactivated polio vaccine. a Proportions are no. of seropositive participants/total no. of participants.
by serostatus at day 0), and Figure 1 (which presents type-specific relative cumulative distribution curves, by study arm).
Seroconversion
All seronegative participants seroconverted to the 3 serotypes by day 7, except for 1 participant in the IPV arm, who did not seroconvert to poliovirus type 3 by day 56. There were no significant differences in seroconversion rates between the study arms for any serotype: the percentage with seroconversion at day 56 was 100% for serotypes 1 and 2 in both the fIPV and IPV arms and 100% and 98.7% for serotype 3 in the fIPV and IPV arms, respectively (P = .469).
Antibody Titers
At baseline (day 0), median titers were low (<50) for all serotypes. At day 7, there was a significant increase in median titers from day 0, but although titers were high, they were consistently lower for the fIPV arm as compared to the IPV arm for all 3 serotypes, with titers of 3573 (95% CI, 2839-4499) in the fIPV arm and 4499 (95% CI, 4499 to ≥5664) in the IPV arm against serotype 1 (P < .001), 2839 (95% CI, 1791-3573) in the fIPV arm and 4499 (95% CI, 4499 to ≥5664) in the IPV arm (P < .001) against serotype 2, and ≥5664 (95% CI, ≥5664 to ≥5664) in the fIPV arm and ≥5664 (95% CI, ≥5664 to ≥5664) in the IPV arm (P < .001) against serotype 3. However, by day 28, while differences between the study arms remained statistically significant, the magnitude of the significance had decreased (P = .040, P = .006, and P = .035 for poliovirus type 1, 2, and 3, respectively) and remained low through to day 56 (P = .023, P = .024, and P = .384 for poliovirus types 1, 2, and 3, respectively). There was very little change in titers for either study arm between days 28 and 56 (ie, after receipt of the second dose of vaccine) ( Table 3) . Abbreviations: fIPV, fractional-dose inactivated polio vaccine; IPV, inactivated polio vaccine. a 95% confidence intervals were calculated using bootstrapping with 10 000 replications.
b P values were calculated using the Wilcoxon rank sum test.
Overall Immune Response
The overall immune response was defined as either seroconversion or a >4-fold increase in titer. More than 92% participants had an immune response by day 7, and >94% participants had an immune response at days 28 and 56 for all serotypes in both study arms. Immune response rates between the study arms were statistically significant at day 7 for poliovirus type 1 (92.6% in the fIPV arm, and 98.4% in the IPV arm; P = .002) and type 2 (92.6% in the fIPV arm, and 97.6% in the IPV arm; P = .012) but not for type 3 (97.3% in the fIPV arm, and 98.4% in the IPV arm; P = .545). However, by days 28 and 56, these differences were no longer significant for any serotype ( Table 4) . The results of the noninferiority analysis are displayed in Table 5 . The difference in proportion of participants with immune response between the study arms demonstrated noninferiority of fIPV as compared to IPV (ie, the upper limit of the 95% CI of the difference was <10%) for all poliovirus serotypes at days 7, 28, and 56. By day 28, there is clear evidence for noninferiority for all serotypes (ie, the upper limits of the 95% CI of the difference were 6.4%, 2.4%, and 2.7% for types 1, 2, and 3, respectively).
Adverse Events
For reactogenicity, no serious adverse events were reported. A total of 10.5% (95% CI, 7.3%-14.7%) in the fIPV arm and 7.1% (95% CI, 4.6%-10.9%) in the IPV arm recorded an adverse event at any time report (ie, 1 hour, 48 hours, 72 hours, and 7 days), but these differences were not statistically significant (P = .564; Table 6 ). In total, 73 adverse events were reported.
DISCUSSION
Our study demonstrated that (1) all but one of the adults who had previously received OPV responded with an anamnestic response following receipt of a booster dose with fIPV; (2) the rapidity and magnitude of the antibody titer increases in all study arms was remarkable, with the demonstration of high levels of antibody against all 3 serotypes 7 days after vaccination; (3) this boosting immune response was independent of whether antibodies were detectable before vaccination; (4) the increase in antibody level to the final titer was slightly slower for the fIPV study arms; and (5) a second IPV dose did not contribute to further boosting of antibody titers.
IPV has been shown to rapidly boost antibody titers in previously vaccinated individuals [27] , but such data were lacking for fIPV in adults who had received their previous dose of OPV during childhood (<4 years of age) and had not received any dose of poliovirus vaccine in the past 20 years. Most importantly, we achieved noninferiority with a fractional dose at days 7, 28, and 56 for all serotypes.
The kinetics of the antibody titer increases demonstrated that, 7 days after fIPV administration, the titers were already extremely high (median reciprocal titer, ≥2839). The kinetics of antibody titer increases were similar to those after a second IPV dose in a previous study from Cuba [20] , involving children aged 12-20 months to whom IPV was administered approximately 1 year after completion of a 2-dose OPV schedule and in whom the rapidity of the increase in antibody titer at 3 and 7 days was measured. In these children, a relatively small proportion (approximately 10%) demonstrated an increase in antibody titer by day 3, but most had an increase at day 7 [20] . Generally, IPV can boost antibody titers in previously immune individuals very rapidly if the titers are low [19, 28] .
Interestingly, the boosting response did not differ on the basis of whether the participants had detectable antibody at vaccination, confirming that individuals without detectable titers had preexisting immunity (either their antibody titers had waned or, less likely, they had been primed 20 years earlier). Nevertheless, the antibody titers in nondetectable antibody titer arm were high, with the lowest median reciprocal titer of 898, but they were significantly lower as compared to the detectable antibody arm, regardless of whether these individuals were in the fIPV arm or the IPV arm. And finally, a second dose of IPV did not contribute to further immunogenicity gains. The single individual who did not seroconvert (to poliovirus type 3) after a single dose also did not seroconvert (to poliovirus type 3) after a second dose. Similarly, the median antibody titers were all lower at the day 56 visit (28 days after a second dose of IPV), suggesting that titers had already started to decline after day 30, but because they were still very high when a second dose was administered, this second dose was not able to boost these levels further.
The data did not give rise to any safety concerns. No serious adverse events were reported, and the frequency and severity of minor adverse events was in line with previous reports [20, 29] . All of these adverse events resolved rapidly.
Our study had limitations. We restricted enrollment to male adults and therefore cannot extrapolate these findings directly to adult women. However, in another study, where we were able to stratify participants by sex, we did not find any difference in immunogenicity by sex [18] .
Our study data contribute to an increasing scientific evidence base [20] [21] [22] . From our data, we can comfortably conclude that a boosting dose of fIPV in previously vaccinated adults leads to rapid boosting of antibody titers and results in detectable antibody titers. This should not be confused with seroconversion, because the kinetics of the antibody response suggest that these adults had preexisting immunity but that antibody titers had waned below detectable levels.
The interpretation of findings from other studies is less obvious. Noninferiority measured by seroconversion was not achieved with fIPV in naive infants [18, 28] and also in boosting of infants and young children [21, 22] . Furthermore, dose-by-dose comparisons of antibody titers demonstrate that fIPV induces lower levels of antibody. In addition, in all studies that evaluated priming, a substantial proportion of participants without seroconversion demonstrated a priming immune response [19, 28] . The public health relevance of these findings is not known.
Recently, in response to further IPV supply decreases, a 2-dose schedule of fIPV has received more attention [28] . Such a schedule could preserve limited supplies (approximately 60% dose sparing) and gives better immunogenicity to all serotypes, including type 2 poliovirus. In Bangladesh, 39% seroconverted following receipt of a full dose at age 6 weeks, compared with 81% following receipt of 2 fIPV doses given at 6 and 14 weeks [28] . In Cuba, 63% seroconverted after receipt of a full dose at age 4 months, compared with 98% after receipt of 2 fIPV doses at ages 4 and 8 months [19] .
There are remaining research gaps. Although we demonstrated rapid boosting of humoral immunity after 2 decades, we have not demonstrated that fIPV also rapidly boosts mucosal immunity, as had been demonstrated for full-dose IPV in India [9] . This question was not addressed in our study. However, recent evidence suggests that mucosal immunity does not differ after receipt of fIPV as compared to IPV [17, 28] .
In conclusion, our study suggests that fIPV could be used in all individuals previously vaccinated against polio, such as in campaigns to control outbreaks. This option is both cost and dose sparing, allowing limited IPV to be stretched to vaccinate additional individuals. Nevertheless, the program and logistic challenges need to be considered.
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